Published in Transl Lung Cancer Res on April 01, 2015
Vandetanib in Advanced NSCLC With RET Rearrangement | NCT01823068
Ponatinib in Advanced NSCLC w/ RET Translocations | NCT01813734
EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer (EUCROSS) | NCT02183870
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. Oncologist (2016) 1.52
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol (2016) 0.99
Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci (2016) 0.88
Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther (2016) 0.82
Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Oncol Rep (2017) 0.78
Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. Oncotarget (2016) 0.78
Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks. Biomolecules (2015) 0.77
Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. Nat Commun (2016) 0.76
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma. Oncotarget (2016) 0.75
Former smokers with non-small-cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis. Cancer Med (2016) 0.75
KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer. Mol Med (2016) 0.75
MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget (2016) 0.75
Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. Cancer Med (2016) 0.75
A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Am J Cancer Res (2017) 0.75
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today (2017) 0.75
Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. Oncotarget (2017) 0.75
Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. Mol Clin Oncol (2017) 0.75
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res (2011) 4.15
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 3.72
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
ALK in lung cancer: past, present, and future. J Clin Oncol (2013) 2.70
Chipping away at the lung cancer genome. Nat Med (2012) 2.67
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med (2013) 2.65
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res (2012) 2.53
New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol (2013) 2.25
Anchored multiplex PCR for targeted next-generation sequencing. Nat Med (2014) 2.25
Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol (2013) 2.22
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer (2014) 1.68
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer (2014) 1.65
ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol (2013) 1.52
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res (2013) 1.51
Molecular analysis for therapy choice: NCI MATCH. Semin Oncol (2014) 1.47
The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer (2013) 1.46
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol (2013) 1.38
A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol (2013) 1.37
FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res (2014) 1.36
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov (2014) 1.19
Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther (2014) 1.19
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol (2012) 1.18
Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer (2013) 1.13
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res (2014) 1.11
Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol (2013) 1.09
RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci (2013) 1.09
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn (2014) 1.06
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol (2014) 1.03
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci (2013) 0.93
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer (2014) 0.92
Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples. Transl Oncol (2014) 0.91
Mouse model for ROS1-rearranged lung cancer. PLoS One (2013) 0.88
Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. J Thorac Oncol (2014) 0.85
Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case. Med Oncol (2014) 0.84
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. J Clin Oncol (2012) 0.83
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. Carcinogenesis (2014) 0.82
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. Clin Lung Cancer (2014) 0.79